Select a medication above to begin.
Depo-Estradiol
estradiol cypionate
Black Box Warnings .
Endometrial Cancer with Unopposed Estrogen in Patients with Intact Uterus
unopposed estrogen use incr. risk of endometrial CA in patients with intact uterus; adding progestogen has been shown to decr. risk of endometrial hyperplasia, a possible precursor to endometrial CA; perform adequate diagnostic measures (including directed or random endometrial sampling) to rule out malignancy in menopausal patient with abnormal genital bleeding of unknown etiology
Adult Dosing .
Dosage forms: INJ: 5 mg per mL
vasomotor symptoms, moderate-severe menopausal
- [1-5 mg IM q3-4wk]
- Info: add progestogen x10-14 days/4wk cycle if intact uterus; use lowest effective estrogen dose, shortest effective tx duration
hypoestrogenism, hypogonadal
- [1.5-2 mg IM q4wk]
- Info: add progestogen x10-14 days/4wk cycle if intact uterus
transgender hormone therapy, feminizing (off-label)
- [2-10 mg IM qwk]
- Info: adjust dose based on patient tx goals, clinical response, and estradiol levels; refer to WPATH or Endocrine Society guidelines
renal dosing
- [see below]
- renal disease: not defined, caution advised
- HD/PD: not defined, caution advised
hepatic dosing
- [see below]
- hepatic impairment: contraindicated
Peds Dosing .
Peds dosing is currently unavailable or not applicable for this drug.